Detail akcie Eisai online

Business Summary: Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
Financial Summary: BRIEF: For the nine months ended 31 December 2023, Eisai Co Ltd revenues increased 1% to Y551.26B. Net income applicable to common stockholders decreased 26% to Y29.1B. Revenues reflect Pharmaceutical Business segment increase of 3% to Y528.07B, Other Business segment increase of 62% to Y23.19B, America segment increase of 6% to Y172.11B, EMEA segment increase of 7% to Y56.17B, Asia/Latin America segment increase of 9% to Y41.41B.